Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2025 16:15 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
September 04, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 13, 2024 06:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 09, 2024 07:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 08, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
July 02, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
May 30, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 28, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 09, 2024 16:10 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
March 26, 2024 06:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update